Potvin C in the EU [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2013-04-17 04:31 (4312 d 04:09 ago) – Posting: # 10425
Views: 45,192

Hi Hötzi,

❝ new experiences from an ongoing MRP. Two studies (first one in two groups due to logistic reasons), Method C (!), all metrics in both studies passed in stage 1 (>80% power in the interim, no α-adjustment = 90% CIs).


Ahhh... MRP - a relic from the bygone ages when your grandad walked around in the snowy alps with bow and arrows looking for deer.

❝ Studies’ models in stage 1:

  1. Fixed:  sequence, period, treatment, group, group × treatment

    Random: subject(sequence)

  2. Fixed:  sequence, period, treatment

    Random: subject(sequence)

Accepted by Germany (RMS); no comments from Austria, Denmark, Sweden, and The Netherlands. Spain: “Statistical analysis should be GLM. Please justify. Please provide the NOL.”

❝ OK, I will repeat the analyses with all fixed effects (sigh; identical CIs…). ;-)


Anything to please the assessor. I have a feeling the assessor means LM but might not know what that really means since every LM in SAS is done via PROC GLM.
But honestly, group x treatment?? I'd rather not go down that road. I hope you do not make precedence.

❝ BTW, does anybody know what “NOL” means?


I am fairly sure it is either "No Objection Lertificate" or "Nixon's Obstructive Leprosy". I don't see what else it could possibly be.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,668 registered users;
157 visitors (0 registered, 157 guests [including 12 identified bots]).
Forum time: 07:40 CET (Europe/Vienna)

Science is wonderfully equipped to answer the question “How?”
but it gets terribly confused when you ask the question “Why?”    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5